GMAB
NASDAQ
$27.91
Genmab (GMAB)
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $36.92 (+32.28%)
Market Cap
$19B
Forward P/E
16.95
P/E Ratio
140.29
Free Cash Flow Yield
0.74%
Price Chart
Valuation
Market Cap$19B
P/E140.29
Forward P/E16.95
PEG1.91
P/S4.58
P/B3.10
Profitability
Total Revenue (TTM)$603M
Gross Profit (TTM)$563M
EBITDA$191M
Profit Margin5.9%
Operating Margin25.1%
EPS$0.21
Financial Health
Debt-to-Equity94.2%
Free Cash Flow Yield0.74%
Growth & Risk
EPS 5Y CAGR-30.81%
Revenue 5Y CAGR-18.28%
FCF 5Y CAGR-30.56%
Beta (5Y)0.59
Sharpe Ratio0.75